COSCIENS Biopharma Statistics
COSCIENS Biopharma (0UGB) Stock Statistics & Valuation Metrics
Total Valuation
COSCIENS Biopharma has a market cap or net worth of CAD 8.37M. The enterprise value is CAD 1.56M.
- Market Cap
- CAD 8.37M
- Enterprise Value
- CAD 1.56M
Share Statistics
COSCIENS Biopharma has 996,394 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 996,394
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
COSCIENS Biopharma’s return on equity (ROE) is -2.75 and return on invested capital (ROIC) is -59.02%.
- Return on Equity (ROE)
- -2.75
- Return on Assets (ROA)
- -0.49
- Return on Invested Capital (ROIC)
- -59.02%
- Return on Capital Employed (ROCE)
- -0.60
- Revenue Per Employee
- 272.47K
- Profits Per Employee
- -376.40K
- Employee Count
- 28
- Asset Turnover
- 0.36
- Inventory Turnover
- 3.78
Valuation Ratios
The current PE Ratio of COSCIENS Biopharma is -0.46. COSCIENS Biopharma’s PEG ratio is -0.01.
- PE Ratio
- -0.46
- PS Ratio
- 0.73
- PB Ratio
- 0.42
- Price to FCF
- -1.60
- Price to Operating Cash Flow
- -1.70
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, COSCIENS Biopharma had revenue of 7.63M and earned -10.54M in profits. Earnings per share was -29.97.
- Revenue
- 7.63M
- Gross Profit
- 2.69M
- Operating Income
- -10.62M
- Pretax Income
- -10.53M
- Net Income
- -10.54M
- EBITDA
- -9.41M
- Earnings Per Share (EPS)
- -29.97
Cash Flow
In the last 12 months, operating cash flow was -3.69M and capital expenditures -46,873, giving a free cash flow of -3.74M billion.
- Operating Cash Flow
- -3.69M
- Free Cash Flow
- -3.74M
- Free Cash Flow per Share
- -3.57
Dividends & Yields
COSCIENS Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -62.70%
- Earnings Yield
- -75.70%
Stock Price Statistics
- Beta
- -0.10
- 52-Week Price Change
- -16.81%
- 50-Day Moving Average
- 8.55
- 200-Day Moving Average
- 10.29
- Relative Strength Index (RSI)
- 71.47
- Average Volume (3m)
- 50
Important Dates
COSCIENS Biopharma upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
COSCIENS Biopharma as a current ratio of 3.18, with Debt / Equity ratio of 55.93%
- Current Ratio
- 3.18
- Quick Ratio
- 2.82
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 0.55
- Interest Coverage Ratio
- -62.15
Taxes
In the past 12 months, COSCIENS Biopharma has paid 10.17K in taxes.
- Income Tax
- 10.17K
- Effective Tax Rate
- -0.00
Enterprise Valuation
COSCIENS Biopharma EV to EBITDA ratio is -0.74, with an EV/FCF ratio of -0.71.
- EV to Sales
- 0.32
- EV to EBITDA
- -0.74
- EV to Free Cash Flow
- -0.71
- EV to Operating Cash Flow
- -0.72
Balance Sheet
COSCIENS Biopharma has CAD 5.27M in cash and marketable securities with CAD 1.95M in debt, giving a net cash position of CAD 3.32M billion.
- Cash & Marketable Securities
- CAD 5.27M
- Total Debt
- CAD 1.95M
- Net Cash
- CAD 3.32M
- Net Cash Per Share
- CAD 3.33
- Tangible Book Value Per Share
- CAD 14.15
Margins
Gross margin is 45.30%, with operating margin of -58.56%, and net profit margin of -57.93%.
- Gross Margin
- 45.30%
- Operating Margin
- -58.56%
- Pretax Margin
- -53.56%
- Net Profit Margin
- -57.93%
- EBITDA Margin
- -43.39%
- EBIT Margin
- -58.56%
Analyst Forecast
The average price target for COSCIENS Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -13.00%
- EPS Growth Forecast
- 75.31%
